Violation Tracker Parent Company Summary
|Top 5 Offense Groups (Groups Defined)||Penalty Total||Number of Records|
|Top 5 Primary Offense Types||Penalty Total||Number of Records|
|off-label or unapproved promotion of medical products||$1,608,100,000||9|
|Foreign Corrupt Practices Act||$29,398,734||1|
|False Claims Act and related||$1,650,000||1|
Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the Update Log, which may vary from what was the case when a violation occurred. The penalty totals are adjusted to account for the fact that the individual entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. The totals are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the list below.
For an overview of this company's accountability track record, read its Corporate Rap Sheet here.
Subsidy Tracker data on financial assistance to this company by federal, state and local government agencies can be found here.
For an overview of assistance this company is receiving under the CARES Act, see its Covid Stimulus Watch summary page here.
Individual Penalty Records:Click on the company or penalty amount for more information on each case.
|Company||Primary Offense Type||Year||Agency||Penalty Amount|
|Eli Lilly and Company||Foreign Corrupt Practices Act||2012||SEC||$29,398,734|
|Eli Lilly & Co.||privacy violation||2002||MULTI-AG||$160,000|
|Eli Lilly and Company||off-label or unapproved promotion of medical products||2009||MULTI-AG||(*) $361,828,456|
|Eli Lilly and Company||off-label or unapproved promotion of medical products||2008||MULTI-AG||$62,000,000|
|Eli Lilly||off-label or unapproved promotion of medical products||2010||MS-AG||$18,500,000|
|Eli Lilly||False Claims Act and related||2013||LA-AG||$1,650,000|
|Eli Lilly||off-label or unapproved promotion of medical products||2010||LA-AG||$20,000,000|
|ELI LILLY & CO LTC||environmental violation||2019||IN-ENV||$45,000|
|Eli Lilly and Co.||off-label or unapproved promotion of medical products||2009||ID-AG||$13,000,000|
|Eli Lilly and Company||off-label or unapproved promotion of medical products||2009||FDA||$1,415,000,000|
|Eli Lilly and Company||off-label or unapproved promotion of medical products||2005||FDA||$36,000,000|
|Boehringer Ingelheim Vetmedica, Inc.||environmental violation||2012||EPA||$68,475|
|Boehringer Ingelheim Vetmedica, Inc.||environmental violation||2011||EPA||$300,000|
|LILLY DEL CARIBE INC||environmental violation||2000||EPA||$39,000|
|LILLY DEL CARIBE, INC.||environmental violation||2000||EPA||$90,000|
|Lilly Del Caribe, Inc.||environmental violation||2003||EPA||$68,992|
|ELI LILLY AND COMPANY||environmental violation||2011||EPA||$337,500|
|ELI LILLY & COMPANY - TIPPECANOE LABS||environmental violation||2009||EPA||$12,000|
|BOEHRINGER INGELHEIM VETMEDICA, INC||environmental violation||2011||EPA||$900,000|
|BOEHRINGER INGELHEIM VETMEDICA, INC||environmental violation||2012||EPA||(*) $338,475|
|Imclone Systems, Inc.||employment discrimination||2005||EEOC||$85,000|
|Eli Lilly and Co.||off-label or unapproved promotion of medical products||2009||CT-AG||$25,100,000|
|Eli Lilly||off-label or unapproved promotion of medical products||2010||AR-AG||$18,500,000|